Dr Reddys Labs

Motilal Oswal recommended Neutral rating on Dr Reddys Labs with a target price of Rs 1250 in its research report dated December 12, 2025.

Neutral Dr Reddys Labs; target of Rs 1250: Motilal Oswal

Motilal Oswal recommended Neutral rating on Dr Reddys Labs with a target price of Rs 1250 in its research report dated October 25, 2025.

Neutral Dr Reddys Labs; target of Rs 1190: Motilal Oswal

Motilal Oswal recommended Neutral rating on Dr Reddys Labs with a target price of Rs 1190 in its research report dated July 23, 2025.

Dr Reddy's Labs Q4 Results: Net profit rises 22% to Rs 1,594 crore on strong generics, NRT boost, beats estimates

Dr Reddy's Labs Q4 results: Revenue from North America rose 9% to Rs 3,559 crore, while revenue in Europe more than doubled to Rs 1,276 crore

Neutral Dr Reddys Labs; target of Rs 1330: Motilal Oswal

Motilal Oswal recommended Neutral rating on Dr Reddys Labs with a target price of Rs 1330 in its research report dated January 24, 2025.

Dr Reddy's surges 4% on Nuvama upgrade to 'buy', bullishness on efforts to mitigate Revlimid expiry impact

Nuvama expect Dr Reddy's new launches--Semaglutide and Abatacept to offset revenue losses and 80% of EBITDA impact from the Revlimid patent expiry in 2026.

Dr Reddy's Labs top Nifty gainer, surges 9% in three sessions

Nomura recently upgraded its rating on Dr Reddy's to "buy," lauding the company's increased capex in FY25, which it sees as a strong indication of the company's commitment to future growth.

Dr Reddy's launches cancer drug Toripalimab in India

In 2023, Dr Reddy's signed a licensing and commercialization agreement with Shanghai Junshi Biosciences for Toripalimab which granted the drugmaker exclusive rights to develop and market Toripalimab in 21 countries.

Gainers & Losers: Stocks and sectors that moved the most on November 6

Emkay Institutional Equities analysts suggested that a Republican sweep may trigger an initial rally and short-term boost for India from foreign inflows, though sustained gains will depend on earnings growth and stable valuations amidst challenges.

Lack of strong launch pipeline keep brokerages neutral over Dr Reddy's Labs

Even though Dr Reddy's showcased decent earnings performance after adjusting for one-offs in Q2, the absence of a strong launch pipeline keep brokerages cautious over its growth outlook.

Neutral Dr Reddy’s Labs; target of Rs 6,070: Motilal Oswal

Motilal Oswal recommended accumulate rating on Dr Reddy’s Labs with a target price of Rs 6,070 in its research report dated May 07, 2024.

Dr Reddy's Labs CFO Parag Agarwal to retire on July 31, MV Narasimham elevated

Agarwal will also cease to be a member of the Management Council and Senior Management Personnel of the company and will continue to be available with till August 31, 2024.

What’s after Revlimid for Dr Reddy’s, Cipla, and Sun Pharma?

The patent on Revlimid expires in January 2026 and the three pharma majors, which have seen strong growth on the back of this drug, are looking for other opportunities to keep their growth path. They appear to have aces up their sleeves.